ImmVirX appoints Dr. Oksana Zdanska as Medical Director

Melbourne, Australia, 16 April 2024 – ImmVirX Pty Limited, a life sciences company dedicated to pioneering the next generationof receptor-targeted immunotherapies for patients confronted with common yet formidable cancers, is pleased to announce the appointment of Dr Oksana Zdanska as Medical Director, commencing today.

Dr. Zdanska is a highly regarded clinical leader with extensive experience in clinical trials, including drug development of novel treatments.  She has know-how and familiarity with cutting edge technologies including the use of oncolytic immunotherapies in clinical settings.

Dr. Zdanska has spent several years in roles of increasing responsibility in clinical research at the Kinghorn Cancer Centre in Sydney, Australia. She has gained extensive experience in clinical trials including drug development of new therapies with different modes of delivery, cancer genomics, genetically modified organisms, health services management, and laboratory operations. She has also taught healthcare courses in a university MBA program.

She trained in the Czech Republic and graduated as a Doctor of Medicine from the First Faculty of Medicine at Charles University in Prague.

Dr Malcolm McColl, ImmVirX CEO, commented, “We are very pleased to welcome Oksana to our team at this exciting time for ImmVirX. She joins the company with an existing deep understanding of our programme, having been a key part of the team at the Kinghorn Cancer Centre, one of Australia’s leading clinical trial sites. She brings to this role an extensive technical knowledge of cancer therapeutics, together with the drive to deliver outcomes. We look forward to working with Oksana on our mission to improve outcomes for patients with difficult to treat cancers.”

Dr Zdanska commented, “I am thrilled to be joining ImmVirX at this important time as it expands its clinical programme into combination therapy and across indications including colorectal, gastric, ovarian and liver cancer. The company’s platform has the potential to offer positive outcomes for large numbers of patients who presently have little or no treatment alternatives. I am excited by the great progress and encouraging clinical results so far. I look forward to working with Malcolm, Chief Scientific Officer Darren Shafren and the passionate R&D team to unlock the benefits of the platform and to develop new products capable of bringing therapeutic solutions for patients with cancer in need of new treatments.”

About ImmVirX:

ImmVirX is developing novel oncolytic viruses to create powerful new cancer immunotherapy combinations. our lead asset, IVX037, is in clinical studies with further agents in pre-clinical development. Our novel oncolytic immunotherapy harnesses the power of viruses to preferentially infect and kill cancer cells and induce local and systemic anti-tumour immune responses. 

The proprietary bio-selection platform enables the development of RNA viruses targeting specific receptor proteins highly expressed on a range of cancer cell types, allowing them to selectively enter, replicate in, and destroy tumour cells while creating beneficial changes in the tumour micro-environment, potentially leading to the generation of specific innate and adaptive immune responses against cancer cells. 

In this way, the viral candidates are intended to increase the effectiveness of current immunotherapies, primarily immune checkpoint inhibitors and CAR-T cell therapies, in fighting cancers of high unmet need including colorectal, gastric, ovarian and liver cancer. 


Media Contact 

Dr. Malcolm McColl 
Chief Executive Officer, Acting Chairman and Co-Founder  
E: [email protected]